1.       Rahman M, P. Fu, Sehgal A, and Smith M (2000).  Interdialytic weight gain, compliance with dialysis regimen, and age are independent predictors of blood pressure in hemodialysis patients, American Journal of Kidney Disease, vol. 35: 257-265.

2.       B. J. Averbook, P. Fu, J. S. Rao and E. G. Mansour (2002).   A long-term analysis of 1018 melanoma patients by classical Cox regression and tree-structured survival analysis at a major referral center: Implications on the future of cancer staging. Surgery, vol. 132: 589-604.

3.       S. Kadereit, L. S. Deeds, S. E. Haynesworth, O. N. Koc, M. M. Kozik, E. Szekely, K. Daum-Woods, G. W. Goetchius, P. Fu, L. A. Welniak, W. J. Murphy, M. J. Laughlin  (2002).  Mesenchymal Stem Cells (MSC) As A Feeder Layer During Short-Term Umbilical Cord Blood In Vitro Expansion Increases Early Hematopoitic Progenitors. Stem Cells, vol. 20: 573-582.

4.       P. Fu, J. S. Rao, J. Jiang (2002). Robust estimation of multivariate failure data with time-modulated frailty. Journal of Modern Applied Statistical Methods, vol. 1 (2) 367-378.

5.       S. Gupta, T. Hussain, G. T. MacLennan, P. Fu, J. Patel and H. Mukhtar (2003).  Differential Expression of S100A2 and S100A4 During Progression of Human Prostate Adenocarcinoma. Journal of Clinical Oncology, vol. 21 (1), 106-112.

6.       J. Jaroscak, K. Goltry, A. Smith, B. Waters-Pick, P. L. Martin, T. Driscoll, R. Howrey, N. Chao, J. Douville, S. Burhop, P. Fu, J. Kurtzberg (2003).  Augmentation of umbilical cord blood (UCB) transplantation with ex-vivo expanded UCB cells: results of a phase I trial using the AASTROM REPLICELL system. Blood, vol. 101, 5061-5067.

7.       R. J. Ellis, A. Vertocnik, E. Kim, H. Zhou, B. Young, B. Sodee, P. Fu, S. Beddar, V. Colussi, J. P. Spirnak, K. H. Dinchman, M. Resnick, T. J. Kinsella (2003). Four-year Biochemical Outcome after Radioimmunoguided Transperineal Brachytherapy for Patients with Prostate Adenocarcinoma. Int. J. Radiation Oncology Biol. Phys., vol. 57 (2), 362-370.

8.       R. J. Ellis,  A.Vertocnik, B. Sodee, H. Zhou, E. Kim, B. Young, P. Fu, V. Colussi, J. P. Spirnak, K. H. Dinchman, M. Resnick (2003). Combination Conformal Radiotherapy and Radioimmunoguided Transperineal 103Pd Implantation for Patients with Intermediate and Unfavorable Risk Prostate Adenocarcinoma. Brachytherapy, vol. 2 (4), 215-222.

9.        S. Kadereit, G. R. Junge, T. Kleen, M. M. Kozik, B. A. Kaminski, K. Daum-Woods, P. Fu, M. Tary-Lehmann, M. J. Laughlin (2003). Deficient IFN-γ Expression in Umbilical Cord Blood (UCB) T Cells Can Be Rescued by IFN-γ-Mediated Increase in NFATc2 Expression. Journal of Clinical Immunology, vol. 23 (6), 485-497.

10.   N. Hamza, M. Lisgaris, G. Yadavalli, L. Nadeau, R. Fox, P. Fu, H. Lazarus, O. Koc, R. Salata and M. Laughlin (2004). Kinetics of Myeloid and Lymphocyte Recovery and Infectious Complications after Unrelated Umbilical Cord Blood versus HLA-Matched Unrelated Donor Allogeneic Transplantation in Adults. British Journal of Haematology, vol. 124, 488-498.

11.   S. Gupta, V. M. Adhami, M. Subbarayan, G. T. MacLennan, J. S. Lewin, U. O. Hafeli, P. Fu, H. Mukhtar (2004). Suppression of Prostate Carcinogenesis by Dietary Supplementation of Celecoxib in Transgenic Adenocarcinoma of the Mouse Prostate Mice. Cancer Research, vol. 64, 3334-3343.

12.   S. Shukla, G. T. MacLennan, P. Fu, J. Patel, S. R. Marengo, M. I. Resnick and S. Gupta (2004). Nuclear Factor-κB/p65 (Rel A) Is Constitutively Activated in Human Prostate Adenocarcinoma and Correlates with Disease Progression. Neoplasia, vol. 6, 390-400.

13.   P. Fu, J. S. Rao (2004). On a simple method for analyzing multivariate survival data using sample survey methods. Journal of Modern Applied Statistical Methods, vol. 3 (2), 345-356.

14.   P. D. Wadhwa, P. Fu , O. N. Koc, B. W. Cooper, R. M. Fox, R. J. Creger, D. L. Bajor, T. Bedi, M. J. Laughlin, J. Payne , S. L. Gerson, H. M. Lazarus (2005). High-Dose Carmustine, Etoposide, Cisplatin, Autologous Stem Cell Transplant with or without Involved-Field Radiotherapy for Relapsed/Refractory Lymphoma: An Effective Regimen with Low Morbidity and Mortality. Biology of Blood and Marrow Transplantation, vol. 11 (1), 13-22.

15.   M. W. Otieno, P. Fu, R. Collea, C. Whalen, S. C. Remick (2005). Kaposi’s Sarcoma in Patients with and without Human Immunodeficiency Virus Infection in A Tertiary Referral Centers in Kenya. Annals of Tropical Medicine and Parasitology, vol. 99 (1), 81-91.

16.   J. Orem, M. W. Otieno, C. Banura, E. K. Mbidde, J. L. Johnson, L. Ayers, M. Ghannoum, P. Fu, E.G. Feigal, J. Black, C. Whalen, M. Lederman, S. C. Remick (2005). Capacity Building for the Clinical Investigation of Aids Malignancy in East Africa. Cancer Detection and Prevention, vol. 29 (2), 133-145.

17.   A. Cocco, E. Osei, D. Thut, A. Edinger, J. Powers, P. Fu, H. J. Meyerson (2005). Bimodal cell populations are common in chronic lymphocytic leukemia but do not impact overall survival. American Journal of Clinical Pathology, vol. 123 (6), 1-8.

18.   J. Orem, P. Fu, A. Ness, M.W. Otieno, and S.C. Remick (2005).  Oral combination chemotherapy in the treatment of AIDS-associated Hodgkin’s disease.  East African Medical Journal, vol. 82 (9) (suppl.), 144-150.

19.   A. Dowlati, R. Chapman, S. Subbiah, P. Fu, A. Ness, T. Cortas, L. Patrick, S. Reynolds, N. Xu, N. Levitan, P. Ivy, S. Remick (2005). Randomized Phase II Trial of Different Schedules of Administration of Rebeccamycin Analogue as Second Line Therapy of Non-Small Cell Lung Cancer. Investigational New Drugs, vol. 23, 563-567.

20.   S. Shukla, A. Mishra, P. Fu, G. MacLennan, M. I. Resnick, S. Gupta (2005). Up-regulation of insulin-like growth factor binding protein-3 by apigenin leads to growth inhibition and apoptosis of 22Rv1 xenograft in athymic nude mice. The FASEB journal, vol. 19, 2042-2044.

21.   T. Kleen, S. Kadereit, L. R. Fanning, J. Jaroscak, P. Fu, H. J. Meyerson,  L. Kulchycki, L. F. Slivka, M. Kozik, M. Tary-Lehmann, and M. J. Laughlin (2005). Recipient-specific tolerance after HLA-mismatched umbilical cord blood stem cell transplantation, Transplantation, vol. 80 (9), 1316-1322.

22.   W. van Heeckeren, J. Vollweiler, P. Fu, H. Meyerson, A. Simic, B. W. Cooper, M. J. Laughlin, H. M. Lazarus, S. L. Gerson, O. N. Koc (2006). Randomized Comparison of Two B-Cell Purging Protocols for Patients with B-Cell Non-Hodgkin’s Lymphoma:  in Vivo Purging with Rituximab versus Ex-Vivo Purging with CliniMacs CD34+ Cell Enrichment Device. British Journal of Haematology, vol. 132 (1), 42-55.

23.   P. Fu, M. Laughlin and H. Zhang (2006). Comparison of Survival Times in a Transplant Study of Hematologic Disorders. Contemporary Clinical Trials, vol. 27 (2), 174-182.

24.   M. R. Finney, N. J. Greco, S. E. Haynesworth, J. M. Martin, D. P. Hedrick, J. Z. Swan, D. G. Winter, S. Kadereit, M. E. Joseph, P. Fu, V. J. Pompili , M. J. Laughlin (2006). Direct Comparison of Umbilical Cord Blood versus Bone Marrow Derived Endothelial Precursor Cells in Mediating Neovascularization in Response to Vascular Ischemia. Biology of Blood and Marrow Transplantation, vol. 12 (5), 585-593.

25.   M. Yüksel, E. Baron, M. Camouse, B. Cooper, H. Lazarus, S. Gerson, M. Laughlin, K. Cooper, A. Gilliam, P. Fu, S. Stevens, O. N. Koç (2006). Peritransplant Use of Ultraviolet-B Irradiation (UV-B) Therapy Is Detrimental to Allogeneic Stem Cell Transplantation Outcome. Biology of Blood and Marrow Transplantation, vol. 12 (6), 665-671.

26.   P. Fu, R. K. Bagai, H. Meyerson, D. Kane, R. M. Fox, R. J. Creger, B. W. Cooper, S. L. Gerson, M. J. Laughlin, O. N. Koc, H. M. Lazarus (2006). Pre-mobilization Therapy Blood CD34+ Cell Count Predicts The Likelihood Of Successful Hematopoietic Stem Cell Mobilization. Bone Marrow Transplantation, vol. 38, 189-196.

27.   G. T. MacLennan, R. Eisenberg, R. L. Fleshman, J. M. Taylor,  P. Fu, M. I. Resnick, S. Gupta (2006). The Influence of Chronic Inflammation in Prostatic Carcinogenesis: A 5-Year Follow-up Study. The Journal of Urology, vol. 176 (3), 1012-1016.

28.   R. J. Ellis, H. Zhou, E. Kim, P. Fu, D. Kaminsky, B. Sodee, V. Colussi, W. Z. Vance, J. P. Spirnak, C. Kim, M. I. Resnick (2007). Biochemical disease free survival rates following definitive low-dose-rate prostate brachytherapy with dose escalation to biologic target volumes identified with SPECT/CT Capromab Pendetide. Brachytherapy, vol. 6 (1), 16-25.

29.   T. Cortas, R. Eisenberg, P. Fu, J Kern, L. Patrick, A. Dowlati (2007). Activation State EGFR and STAT-3 as Prognostic Markers in Resected Non-Small Cell Lung Cancer. Lung Cancer, vol. 55 (3), 349-355.

30.   R.J. Ellis, H. Zhou, D.A. Kaminsky, P. Fu, E. Kim, D.B.  Sodee, V. Colussi, J. P. Spirnak, C. C. Whalen, M. I. Resnick (2007). Rectal Morbidity following Permanent Prostate Brachytherapy with Dose Escalation to Biological Target Volumes identified by SPECT/CT Fusion. Brachytherapy, vol. 6 (2), 149-156.

31.   A. Dowlati, S. Subbiah, M. Cooney, K. Rutherford, T. Mekhail, P. Fu, R. Chapman, A. Ness, T. Cortas, J. Saltzman, N. Levitan, G. Warren (2007). Phase II Trial of Thalidomide as Maintenance Therapy for Extensive Stage Small Cell Lung Cancer after Response to Chemotherapy. Lung Cancer, vol. 56 (3), 377-381.

32.   E. D. Batts, C. Maisel, D. Kane, L. Liu, P. Fu, T. O’Brien, S. Remick, N. Bahlis, S. L. Gerson (2007). O6-Benzylguanine and BCNU in Multiple Myeloma: a Phase II Trial. Cancer Chemotherapy and Pharmacology, vol. 60, 415-421.

33.   S. Shukla, G. T. MacLennan, C. A. Flask, P. Fu, Anil Mishra, M. I. Resnick, S. Gupta (2007) Blockade of β-Catenin Signaling by Plant Flavonoid Apigenin Suppresses Prostate Carcinogenesis in TRAMP Mice. Cancer Research, vol. 67, 6925-6935.

34.   M. R. Etling, S. Davies, M. Campbell, R. Redline, P. Fu, A. D. Levine (2007). Maturation of mucosal immune system underlies colitis susceptibility in interleukin-10 deficient (IL-10-/-) mice. Journal of Leukocyte Biology, vol. 82, 311-319.

35.   S. Shukla, G. T. MacLennan, D. J. Hartman, P. Fu, M.I. Resnick, S. Gupta (2007). Activation of PI3K-Akt signaling pathway promotes prostate cancer cell invasion. International Journal of Cancer, vol. 121, 1424-1432.

36.   P. Barr, P. Fu, H. Lazarus, D. Kane, H. Meyerson, P Hartman, R. Reyes, R. Creger, K. Stear, M. Laughlin, W. Tse, B. Cooper (2007). Antiangiogenic activity of thalidomide in combination with fludarabine, carboplatin, and topotecan for high-risk acute myelogenous leukemia. Leukemia and Lymphoma, vol. 48 (10), 1940-1949.

37.   W. van Heeckeren, L. R. Fanning, H. Meyerson, P. Fu, H. M. Lazarus, B. W. Cooper, W. Tse,T. L. Kindwall-Keller, J. Jaroscak, M. Finney, R. N. Fox, L. Solchaga, M. Forster, R.  J. Creger, M. J. Laughlin (2007). Influence of HLA Disparity and Graft Lymphocytes on Allogeneic Engraftment and Survival after Umbilical Cord Blood Transplant in Adults. British Journal of Haematoloy. vol.139, 464-474.

38.   B. Overmoyer, P. Fu, C. Hoppel, T. Radivoyevitch, R. Shenk, M. Persons, P. Silverman, K. Robertson, N.P. Ziats, J.K. Wasman, F.W. Abdul-Karim, J. Jesberger, J. Duerk, P. Hartman, S. Hanks, J. Lewin, A. Dowlati, K. McCrae, P. Ivy, S.C. Remick (2007). Inflammatory Breast Cancer as a Model Disease to Study Tumor Angiogenesis:  Results of a Phase IB Trial of Combination SU5416 and Doxorubin. Clinical Cancer Research, vol. 13 (19), 5862-5868.

39.   J. Gibbons, M. J. Egorin, R. K. Ramanathan, P. Fu, D. L. Mulkerin, S. Shibata, C. H. M. Takimoto, S. Mani, P. A. LoRusso, J. L. Grem, A. Pavlick, H. J. Lenz, S. M. Flick, S. Reynolds, T. F. Lagattuta , R. A. Parise, Y. Wang, A. J. Murgo, S. P. Ivy, S. C. Remick (2008). Phase I and Pharmacokinetic Study of Imatinib Mesylate in Patients with Advanced Malignancies and Varying Degrees of Renal Dysfunction.  A Study by the National Cancer Institute Organ Dysfunction Working Group. Journal of Clinical Oncology, vol. 26 (4), 570-576.

40.   P. Fu, W. J. van Heeckeren, P. D. Wadhwa, D. J. Bajor, R. J. Creger, Z. Xu, B. W. Cooper, M. J. Laughlin, S. L. Gerson, O. N. Koç, H. M. Lazarus (2008). Time-Dependent Effect of Non-Hodgkin’s Lymphoma Grade on Disease Free Survival of Relapsed/Refractory Patients treated with High-Dose Chemotherapy plus Autotransplantion. Contemporary Clinical Trials, vol. 29, 157-164.

41.   A. Dowlati, P. Fu (2008). Is Response Rate Relevant to Phase II Trial Design of Targeted Agents? Journal of Clinical Oncology, vol. 26, 1204 – 1205.

42.   R. J. Ellis, E. H. Zhou, P. Fu, D. A. Kaminsky, D. B. Sodee P. F. Faulhaber, D. Bodner, M. I. Resnick (2008). Single Photon Emission Computerized Tomography With Capromab Pendetide Plus Computerized Tomography Image Set Co-Registration Independently Predicts Biochemical Failure. The Journal of Urology, vol. 179 (5), 1768 – 1774.

43.   A. Dowlati, S. Manda, J. Gibbons, S. Remick, L. Patrick, P. Fu (2008). Multi-Institutional Phase I Trials of Anticancer Agents. Journal of Clinical Oncology, vol. 26 (12), 1926-1931.

44.   G Huang, R Eisenberg, M Yan, S Monti, E Lawrence, P. Fu, J Walbroehl, E Lowenberg, T Golub, J Merchan, DG Tenen, S Markowitz, B Halmos (2008). 15-hydroxyprostaglandin dehydrogenase is a target of hepatocyte nuclear factor 3β and a tumor suppressor in lung cancer. Cancer Research, vol. 68, 5040-5048.

45.   C.J. Mooney, G. Nagaiah,  P. Fu, J. K. Wasman, M. M. Cooney, P. S. Savvides, J. A. Bokar, A. Dowlati, D.Wang, S. S. Agarwala, S. M. Flick, P. H. Hartman, J. D. Ortiz, P. N. Lavertu, S. C. Remick (2009). A Phase II Trial of Fosbretabulin in Advanced Anaplastic Thyroid Carcinoma and Correlation of Baseline Serum-Soluble Intracellular Adhesion Molecule-1 with Outcome. Thyroid, vol. 19, 233-240.

46.   J. Baar, P. Silverman, J. Lyons, P. Fu, F. Abdul-Karim, N. Ziats, J. Wasman, P. Hartman, J. Jesberger, L. Dumadag, E. Hohler, R. Leeming, R. Shenk, H. Chen, K. McCrae, A. Dowlati, S. C. Remick, B. Overmoyer (2009). A Vasculature-Targeting Regimen of Pre-Operative Docetaxel with or without Bevacizumab for Locally Advanced Breast Cancer: Impact on Angiogenic Biomarkers. Clinical Cancer Research, vol. 15 (10), 3583-3590.

47.   S. Shukla, M. Shukla, G. T. MacLennan, P. Fu, S. Gupta (2009). Deregulation of FOXO3A during Prostate Cancer Progression. International Journal of Oncology, vol. 34 (6): 1613-1620.

48.   W. O. Mwanda, J. Orem, P. Fu, C. Banura, J. Kakembo, C. A. Onyango, A. Ness, S. Reynolds, J. L. Johnson, V. Subbiah, J. Bako, H. Wabinga, F. K. Abdallah, H. J. Meyerson, C. C. Whalen, M. M. Lederman, J. Black, L.W. Ayers, E. Katongole-Mbidde, S. C. Remick (2009). Dose-Modified Oral Chemotherapy in the treatment of AIDS-Related Non-Hodgkin’s Lymphoma in East Africa. Journal of Clinical Oncology, vol. 27 (21): 3480-3488.

49.   X. Cong, S. M. Ludington-Hoe, G. McCain, P. Fu (2009). Kangaroo Care Modifies Preterm Infant Heart Rate Variability in Response to Heel Stick Pain: Pilot Study. Early Human Development, vol. 85: 561-567.

50.   P. Fu, A. Dowlati, M. Schluchter (2009). Comparison of power between randomized discontinuation design and upfront randomization design on progression free survival. Journal of Clinical Oncology, vol. 27 (25): 4135-4141.

51.   P.M. Barr, P. Fu, H.M. Lazarus, N. Horvath, S.L. Gerson, O.N. Koc, N.J. Bahlis, M.R. Snell, A. Dowlati, B.W. Cooper (2009). Phase I trial of fludarabine, bortezomib, and rituximab for relapsed and refractory indolent and mantle cell non-Hodgkin lymphoma. British Journal of Haematology, vol. 147: 89-96.

52.   A. Dowlati, J. Posey, R. K. Ramanathan, L. Rath, P. Fu, A. Chak, S. Krishnamurthi, J. Brell, S. Ingalls, C. L. Hoppel, P. Ivy, S. C. Remick (2009). Phase II and Pharmacokinetic Trial of Rebeccamycin Analog in Advanced Biliary Cancers. Cancer Chemotherapy and Pharmacology, vol. 65: 73 – 78.

53.   R. S. Leidner, P. Fu, B. Clifford, A. Hamdan, C. Jin, R. Eisenberg, T. J. Boggon, M. Skokan, W. A. Franklin, F. Cappuzzo, F. R. Hirsch, M. Varella-Garcia, B. Halmos (2009). Genetic Abnormalities of the EGFR pathway in African American Patients with Non-Small Cell Lung Cancer. Journal of Clinical Oncology, vol. 27 (33): 5620-5626.

54.   K. Martires, P. Fu, A. M. Polster, K. D. Cooper, E. D. Baron (2009). Factors that affect skin aging: a cohort-based survey on twins. Archives of Dermatology (in press).